iBio, Inc. Q3 2025: Revenue $0.22M, Net Loss $2.25M

Ticker: IBIO · Form: 10-Q · Filed: 2025-05-02T00:00:00.000Z

Sentiment: bearish

Topics: 10-Q, financials, biotech

TL;DR

iBio's Q3 2025 shows $0.22M revenue, $2.25M net loss. Assets $9.86M, Liabilities $3.71M.

AI Summary

iBio, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $9.86 million and total liabilities of $3.71 million. For the three months ended March 31, 2025, iBio reported revenue of $0.22 million and a net loss of $2.25 million.

Why It Matters

This filing provides a snapshot of iBio's financial health and operational performance for the third quarter of fiscal year 2025, impacting investor decisions and market perception.

Risk Assessment

Risk Level: medium — The company reported a net loss, indicating ongoing financial challenges that could pose a risk to its future operations.

Key Numbers

$9.86M — Total Assets (As of March 31, 2025)
$3.71M — Total Liabilities (As of March 31, 2025)
$0.22M — Revenue (For the three months ended March 31, 2025)
$2.25M — Net Loss (For the three months ended March 31, 2025)

Key Players & Entities

iBio, Inc. (company) — Filer
March 31, 2025 (date) — Reporting Period End Date
$9.86 million (dollar_amount) — Total Assets
$3.71 million (dollar_amount) — Total Liabilities
$0.22 million (dollar_amount) — Revenue for the three months ended March 31, 2025
$2.25 million (dollar_amount) — Net Loss for the three months ended March 31, 2025

FAQ

What was iBio's total revenue for the nine months ended March 31, 2025?

The filing indicates that for the nine months ended March 31, 2025, iBio reported total revenue of $0.92 million.

What was the net loss for the nine months ended March 31, 2025?

For the nine months ended March 31, 2025, iBio reported a net loss of $9.20 million.

What are the company's total assets as of March 31, 2025?

As of March 31, 2025, iBio reported total assets of $9.86 million.

What are the company's total liabilities as of March 31, 2025?

As of March 31, 2025, iBio reported total liabilities of $3.71 million.

What was the net loss for the three months ended March 31, 2025?

For the three months ended March 31, 2025, iBio reported a net loss of $2.25 million.

From the Filing

0001420720-25-000025.txt : 20250502 0001420720-25-000025.hdr.sgml : 20250502 20250502082928 ACCESSION NUMBER: 0001420720-25-000025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250502 DATE AS OF CHANGE: 20250502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25905577 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 10-Q 1 ibio-20250331x10q.htm 10-Q iBio, Inc._March 31, 2025 9862000 3713000 9202000 2247000 9862000 3713000 9202000 2247000 0001420720 --06-30 2025 Q3 false 1000000 0.001 0 0 0 275000000 0.001 8623676 10066276 0.49 0.71 1.44 5.43 0.00 0.00 0.14 0.00 2.19 0.49 0.85 1.44 7.62 0.05 0 0 0 0 P3Y P20Y 5000 0.05 0.05 P61D 2.00 0.49 0.71 1.44 5.43 0.00 0.14 0.00 2.19 0.49 0.85 1.44 7.62 P3Y P3Y 1 1 0 0 0 0.00 0001420720 us-gaap:SegmentDiscontinuedOperationsMember ibio:ContractDevelopmentAndManufacturingOrganizationMember ibio:PurchaseAndSaleAgreementMember 2024-05-17 2024-05-17 0001420720 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001420720 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001420720 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001420720 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001420720 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001420720 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001420720 ibio:RubrycTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember ibio:StockPurchaseAgreementMember 2021-08-23 2021-08-23 0001420720 us-gaap:CommonStockMember 2023-11-29 2023-11-29 0001420720 2023-11-29 2023-11-29 0001420720 us-gaap:RetainedEarningsMember 2025-03-31 0001420720 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001420720 us-gaap:RetainedEarningsMember 2024-12-31 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001420720 2024-12-31 0001420720 us-gaap:RetainedEarningsMember 2024-09-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001420720 2024-09-30 0001420720 us-gaap:RetainedEarningsMember 2024-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001420720 us-gaap:RetainedEarningsMember 2024-03-31 0001420720 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001420720 us-gaap:RetainedEarningsMember 2023-12-31 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001420720 2023-12-31 0001420720 us-gaap:RetainedEarningsMember 2023-09-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001420720 2023-09-30 0001420720 us-gaap:RetainedEarningsMember 2023-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001420720 ibio:FirstInsuranceFundingMember us-gaap:NotesPayableOtherPayablesMember ibio:InsurancePremiumFinancingAgreementMember 2025-03-31 0001420720 ibio:FirstInsuranceFundingLoan2Member us-gaap:NotesPayableOtherPayablesMember ibio:InsurancePremiumFinancingAgreementMember 2025-03-31 0001420720 ibio:WoodforestNationalBankMember us-gaap:NotesPayableToBanksMember ibio:CreditAgreementWithWoodforestNationalBankMember 2025-03-31 0001420720 us-gaap:CommonStockMember 2025-03-31 0001420720 us-gaap:CommonStockMember 2024-12-31 0001420720 us-gaap:CommonStockMember 2024-09-30 0001420720 us-gaap:CommonStockMember 2024-06-30 0001420720 us-gaap:CommonStockMember 2024-03-31 0001420720 us-gaap:CommonStockMember 2023-12-31 0001420720 us-gaap:CommonStockMember 2023-09-30 0001420720 us-gaap:Common